US 12048699
Cancer treatment methods based on TP53 mutation status and hypermutation
granted A61KA61K31/519A61P
Quick answer
US patent 12048699 (Cancer treatment methods based on TP53 mutation status and hypermutation) held by Takeda Pharmaceutical Company Limited expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/519, A61P, A61P35/00